Amraee A, Mokhayeri Y, Gholami M, Resane S, Evazi M R, Abbasi M, Sadr M, Shamsi Sh, Tayebzadeh P, Jahani A, Darvish L
Department of Medical Physics, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Cardiovascular Research Center, Shahid Rahimi Hospital, Lorestan University of Medical Sciences, Khorramabad, Iran.
Clin Transl Oncol. 2025 Mar;27(3):805-815. doi: 10.1007/s12094-024-03632-z. Epub 2024 Aug 5.
In recent years, evidence has accumulated that a second method of conserving the breast from cancer with re-irradiation as part of treatment may be feasible and safe. Many oncologists are skeptical of breast re-irradiation due to concerns about late complications, so access to quantitative data on the prevalence of breast re-irradiation complications is very important. In this meta-analysis, we determine the prevalence of complications in normal tissue after breast re-irradiation.
A search was done to recognize qualified studies using EMBASE, MEDLINE, PUBMED, Google Scholar, and Cochrane Collaboration Library electronic databases from 2000 to 2023. In total, ten primary studies were applied in this meta-analysis to estimate the prevalence of complications of disorders, skin fibrosis, and chest pain. Heterogeneity was investigated using the I index and the meta-regression to evaluate variables suspected of causing heterogeneity. Statistical analysis and synthesis were performed using Stata 17.
The average dose received by patients who underwent radiation therapy in two stages was 100.32 Gy, and in these patients, the prevalence of skin fibrosis and disorders was 47% (95% CI 71-22%; I = 96.76%, P < 0.001) and the prevalence of chest pain was 35% (95% CI 68-8%; I = 98.13%, P < 0.001).
There is little clinical information about the incidence of complications in breast re-irradiation therapy. This meta-analysis presents the prevalence of complications after breast re-irradiation to help radiation oncologists and physicists make better decisions.
近年来，越来越多的证据表明，作为治疗一部分的再次放疗用于保乳的第二种方法可能是可行且安全的。由于担心晚期并发症，许多肿瘤学家对乳房再次放疗持怀疑态度，因此获取有关乳房再次放疗并发症发生率的定量数据非常重要。在这项荟萃分析中，我们确定了乳房再次放疗后正常组织中并发症的发生率。
通过检索EMBASE、MEDLINE、PUBMED、谷歌学术和Cochrane协作图书馆电子数据库，识别2000年至2023年的合格研究。本荟萃分析共纳入10项主要研究，以评估疾病、皮肤纤维化和胸痛并发症的发生率。使用I指数和荟萃回归研究异质性，以评估怀疑导致异质性的变量。使用Stata 17进行统计分析和综合。
接受两阶段放疗的患者平均剂量为100.32 Gy，在这些患者中，皮肤纤维化和疾病的发生率为47%（95%CI 71-22%；I=96.76%，P<0.001），胸痛的发生率为35%（95%CI 68-8%；I=98.13%，P<0.001）。
关于乳房再次放疗治疗中并发症发生率的临床信息很少。这项荟萃分析展示了乳房再次放疗后并发症的发生率，以帮助放射肿瘤学家和物理学家做出更好的决策。
